A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy William.

Slides:

Advertisements

Similar presentations

Neutron radiation therapy for advanced thyroid cancers Tobias R. Chapman, MD, George E. Laramore, PhD, MD, Stephen R. Bowen, PhD, Peter F. Orio, DO, MS.

Advertisements

Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial K. Ranh Voong, MD MPH, Lincy S. Lal, PhD, Deborah.

Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate.

Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes Stuart E. Samuels, MD, PhD, Matthew.

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer Victor E. Chen, BS, Erin.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

John Boyle, MD, Brad Ackerson, MD, Lin Gu, MS, Chris R. Kelsey, MD

Palliative radiation therapy for superior vena cava syndrome in metastatic Wilms tumor using 10XFFF and 3D surface imaging to avoid anesthesia in a pediatric.

Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports Daniel K. Ebner, BS, Tadashi Kamada, MD, PhD,

Incorporating big data into treatment plan evaluation: Development of statistical DVH metrics and visualization dashboards Charles S. Mayo, PhD, John.

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity Sarah J. Stephens, MD, Samantha Thomas, MB,

Jerry D Slater, M. D. , Carl J Rossi, M. D. , Les T Yonemoto, M. D

Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate.

Sociodemographic disparities in the utilization of proton therapy for prostate cancer at an urban academic center Kristina D. Woodhouse, MD, Wei-Ting.

Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial Daniel A. Hamstra, MD, PhD, Neil Mariados,

Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions Chelsea.

Efficacy and toxicity of rectal cancer reirradiation using IMRT for patients who have received prior pelvic radiation therapy Fady F. Youssef, MS, Parag.

Dosimetric analysis of varying cord planning organ at risk volume in spine stereotactic body radiation therapy Dawn Owen, MD, PhD, Charles S. Mayo, PhD,

New-onset Atrial Fibrillation Predicts Heart Failure Progression

Detection of late radiation damage on left atrial fibrosis using cardiac late gadolinium enhancement magnetic resonance imaging Y. Jessica Huang, PhD,

Reducing radiation dose and enhancing imaging quality of 4DCT for radiation therapy using iterative reconstruction algorithms George Noid, PhD, An Tai,

Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial Susanne M.

Higher-Than-Conventional Radiation Doses in Localized Prostate Cancer Treatment: A Meta-analysis of Randomized, Controlled Trials Gustavo Arruda Viani,

Effect of variations in atelectasis on tumor displacement during radiation therapy for locally advanced lung cancer Nathan Tennyson, MD, Elisabeth Weiss,

Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and.

Tijana Skrepnik, MD, Silvija Gottesman, MD, Baldassarre Stea, MD, PhD

Charles S. Mayo, PhD, Marc L

Volume 4, Issue 5, Pages (September 2017)

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Volume 11, Issue 8, Pages (August 2014)

Jaden D. Evans, MD, Krishan R

Volume 69, Issue 1, Pages (January 2016)

Jennifer C. Ho, MD, Quynh-Nhu Nguyen, MD, Heng Li, PhD, Pamela K

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials David Moher, MSc, Kenneth F Schulz,

A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial

Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer– specific Mortality: Competition Between Age and Time to Biochemical Failure

Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality.

Perceived Complexity of Various Liver Resections: Results of a Survey of Experts with Development of a Complexity Score and Classification Major K. Lee,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Patterns of regional failure in stage III non-small cell lung cancer treated with neoadjuvant chemoradiation therapy and resection Shalini Garg, MD,

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)

Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic center

A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596):

Effect of Daily and Every Other Day Stereotactic Body Radiation Therapy Schedules on Treatment-Related Fatigue in Patients With Hepatocellular Carcinoma

Burnout and Resiliency in Canadian Oncology Residents: A Nationwide Resident and Program Director Survey Hannah Dahn, MD, Angela McGibbon, MD, David.

Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis William A. Stokes, MD, Brian.

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer Philip E. Lammers, MD, Yu Shyr, PhD, Chung-I Li,

Nilay S. Shah, MD, MPH, David Leonard, PhD, Carrie E

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Volume 14, Issue 9, Pages (August 2013)

Do CIs Give You Confidence?

Long-Term Results of a Phase II Trial of Induction Paclitaxel-Carboplatin Followed by Concurrent Radiation Therapy and Weekly Paclitaxel and Consolidation.

A Phase II Study of Concurrent Chemoradiation with Weekly Docetaxel, Carboplatin, and Radiation Therapy Followed by Consolidation Chemotherapy with Docetaxel.

A Phase I Study of Gefitinib with Concurrent Dose-Escalated Weekly Docetaxel and Conformal Three-Dimensional Thoracic Radiation Followed by Consolidative.

Comparison of Docetaxel- and Vinca Alkaloid–Based Chemotherapy in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis of.

Using Smaller-Than-Standard Radiation Treatment Margins Does Not Change Survival Outcomes in Patients with High-Grade Gliomas Kripa Guram, BS, Mark Smith,

Oncoforum Urology: Prostate Cancer 2008 at a Glance

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced,

Vasiliki A. Moragianni, M. D. , M. S. , Stephanie-Marie L. Jones, M. D

Adjuvant and Salvage Radiation Therapy After Prostatectomy: ASTRO/AUA Guideline Amendment, Executive Summary 2018 Thomas M. Pisansky, MD, Ian M. Thompson,

The play of chance Fertility and Sterility

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin.

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy William C. Jackson, MD, Felix Y. Feng, MD, Stephanie Daignault, PhD, Maha Hussain, MD, David Smith, MD, Kathleen Cooney, MD, Kenneth Pienta, MD, Shruti Jolly, MD, Brent Hollenbeck, MD, Karin B. Olson, PA-C, Howard M. Sandler, MD, Michael E. Ray, MD, PhD, Daniel A. Hamstra, MD, PhD Advances in Radiation Oncology Volume 1, Issue 1, Pages 59-66 (January 2016) DOI: 10.1016/j.adro.2015.11.001 Copyright © 2016 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

Figure 1 (A) Freedom from grade 2+ late urinary toxicity (P = .41) and (B) late rectal toxicity (P = .60). Freedom from (C) biochemical progression (HR, 098 [90% CI, 0.41-2.35], P = .9648) and (D) from metastasis (HR 0.29 [90% CI, 0.07-1.22], P = .918. CI, confidence interval; HR, hazard ratio; SRT, salvage radiation therapy. Advances in Radiation Oncology 2016 1, 59-66DOI: (10.1016/j.adro.2015.11.001) Copyright © 2016 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions